These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15448745)

  • 21. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
    Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
    Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.
    Lichty BD; Keating A; Callum J; Yee K; Croxford R; Corpus G; Nwachukwu B; Kim P; Guo J; Kamel-Reid S
    Br J Haematol; 1998 Dec; 103(3):711-5. PubMed ID: 9858221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
    Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
    Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
    Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.
    Melo JV; Gordon DE; Cross NC; Goldman JM
    Blood; 1993 Jan; 81(1):158-65. PubMed ID: 8417787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML; Li W; Arlinghaus RB
    Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia.
    Kirk JA; Radich J; Edmands S; Lee A; VanDevanter DR; Reems JA; Bryant EM
    Am J Hematol; 1996 Jul; 52(3):129-34. PubMed ID: 8756076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
    Bock O; Reising D; Kreipe H
    Diagn Mol Pathol; 2003 Sep; 12(3):119-23. PubMed ID: 12960692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises.
    Ponzetto C; Guerrasio A; Rosso C; Avanzi G; Tassinari A; Zaccaria A; LoCoco F; Foa R; Basso G; Abate ML
    Br J Haematol; 1990 Sep; 76(1):39-44. PubMed ID: 2223647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH.
    Kim YR; Cho HI; Yoon SS; Park S; Kim BK; Lee YK; Chun H; Kim HC; Lee DS
    Genes Chromosomes Cancer; 2005 May; 43(1):37-44. PubMed ID: 15723338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
    Manley R; Cochrane J; McDonald M; Rigby S; Moore A; Kirk A; Clarke S; Crossen PE; Morris CM; Patton WN
    Leukemia; 1999 Jan; 13(1):126-9. PubMed ID: 10049047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
    Huntly BJ; Bench AJ; Delabesse E; Reid AG; Li J; Scott MA; Campbell L; Byrne J; Pinto E; Brizard A; Niedermeiser D; Nacheva EP; Guilhot F; Deininger M; Green AR
    Blood; 2002 Jun; 99(12):4547-53. PubMed ID: 12036887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.